About this episode

Franck Morschhauser discusses the phase 3 EPCORE FL-1 study on epcoritamab for follicular lymphoma with Ben Abbott.

Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02360-8/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thela...

People in this episode

Host: Ben Abbott

Guest: Franck Morschhauser

Topics covered

• follicular lymphoma
• epcoritamab
• cancer treatment
• clinical trials
• ASH conference

Keywords

• follicular lymphoma
• epcoritamab
• lenalidomide
• rituximab
• clinical trial
• ASH 2025

Mentioned in this episode

Organizations: The Lancet

Products: epcoritamab, lenalidomide, rituximab

Books & works: EPCORE FL-1 study

More episodes of The Lancet in conversation with

• Louise Chappell and Na’ama Carlin on Personal Cancer Stories · February 3, 2026 · 31 min
• Susannah Stanway on the London Global Cancer Week · December 19, 2025 · 24 min
• Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health · December 9, 2025 · 1h 1m
• Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC · October 19, 2025 · 21 min
• Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer · October 17, 2025 · 22 min
• Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden · July 28, 2025 · 21 min

Explore listener stats, chart rankings, contacts and more on the The Lancet in conversation with podcast page.